Humacyte (HUMA) Return on Capital Employed (2021 - 2026)
Humacyte (HUMA) posted quarterly Return on Capital Employed of 117.04% for Q1 2026, down 3176.0% year-over-year from 3.81% in Q1 2025, and up 7.4% quarter-over-quarter from 126.4% in Q4 2025.
Humacyte (HUMA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Return on Capital Employed for 6 consecutive years, with 117.04% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3176.0% year-over-year to 117.04%; the TTM figure through Mar 2026 stood at 117.04% (down 3176.0% YoY), while the FY2025 annual figure was 99.44%, up 171.0% from the prior year.
- Return on Capital Employed grew to 117.04% in Q1 2026 per HUMA's latest filing, from 126.4% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 31.44% in Q1 2022 and bottomed at 126.4% in Q4 2025.
- Historically, Return on Capital Employed has averaged 77.09% across 5 years, with a median of 80.88% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed soared 2253 bps — and 2024, when it tumbled 4061 bps.
- Humacyte's Return on Capital Employed stood at 43.25% in 2022, then plunged by 92 bps to 83.07% in 2023, then fell by 29 bps to 107.57% in 2024, then slipped by 17 bps to 126.4% in 2025, then advanced by 7 bps to 117.04% in 2026.
- Business Quant data shows HUMA's Return on Capital Employed at 117.04% in Q1 2026, 126.4% in Q4 2025, and 117.68% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | -101.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -101.63% |
| Mar 31, 2026 | -117.04% |
| Dec 31, 2025 | -126.40% |
| Sep 30, 2025 | -117.68% |
| Jun 30, 2025 | -85.85% |
| Mar 31, 2025 | -85.28% |
| Dec 31, 2024 | -107.57% |
| Sep 30, 2024 | -106.52% |
| Jun 30, 2024 | -80.88% |
| Mar 31, 2024 | -79.60% |
| Dec 31, 2023 | -83.07% |
| Sep 30, 2023 | -65.91% |
| Jun 30, 2023 | -56.97% |
| Mar 31, 2023 | -50.18% |
| Dec 31, 2022 | -43.25% |
| Sep 30, 2022 | -39.13% |
| Jun 30, 2022 | -33.76% |
| Mar 31, 2022 | -31.44% |
| Dec 31, 2021 | -28.60% |
| Sep 30, 2021 | -33.11% |